Table 1 Demographic and serological features of patients who received anti-TNF therapy (n = 60)
Feature | Number (%) or median [IQR] |
|---|---|
Sex | |
Male | 17 (28%) |
Female | 43 (72%) |
Ethnicity | |
Caucasian | 46 (77%) |
Non-Caucasian | 14 (23%) |
Diagnosis | |
Definite JDM | 52 (87%) |
Probable JDM | 2 (3%) |
JDM overlap with scleroderma | 4 (7%) |
JDM overlap with chronic arthritis | 1 (2%) |
Age at disease onset | 5.2 [3.3–9.7] |
Disease duration at anti-TNF start | 3.1 [1.7–4.9] |
Duration on anti-TNF therapy | 2.5 [1.5–4] |
Autoantibody | |
Anti-TIF1γ | 19 (32%) |
Anti-NXP2 | 7 (12%) |
Anti-MDA5 | 1 (2%) |
Anti-Mi2 | 1 (2%) |
Anti-SRP | 1 (2%) |
Anti-PL-7 | 1 (2%) |
Anti-HMGCR | 1 (2%) |
Anti-PMScl | 2 (3%) |
Anti-Topo | 1 (2%) |
Anti-U1RNP and anti-TIF1γ | 1 (2%) |
Unidentified autoantibodies | 13 (22%) |
No-detectable autoantibodies | 11 (19%) |